Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
2018 · JAMA Oncology · 2,473 citations
https://doi.org/10.1001/jamaoncol.2018.3923
J
Joe‐Elie Salem
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
449
Papers
20.3K
Citations
63
h-index
181
i10-index
Joe‐Elie Salem is an academic researcher from Inserm. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Chronic Lymphocytic Leukemia Research & Cardiac electrophysiology and arrhythmias. The author has an h-index of 63, co-authored 382 publications.
ORCID: 0000-0002-0331-3307Papers by this author
works2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
2022 · European Heart Journal · 2,435 citations
https://doi.org/10.1093/eurheartj/ehac244
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
2018 · The Lancet Oncology · 1,149 citations
https://doi.org/10.1016/s1470-2045(18)30608-9
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
2018 · The Lancet · 868 citations
https://doi.org/10.1016/s0140-6736(18)30533-6
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
2022 · European Heart Journal - Cardiovascular Imaging · 459 citations
https://doi.org/10.1093/ehjci/jeac106
Myocarditis in the Setting of Cancer Therapeutics
2019 · Circulation · 419 citations
https://doi.org/10.1161/circulationaha.118.034497
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat